This article is more than 5 years old. Information may no longer be current.
Galapagos discontinues development of novel agent in UC
Galapagos NV has announced it will discontinue clinical development of its G protein-coupled receptor 84 inhibitor, GLPG1205, in ulcerative colitis.
The ORIGIN phase 2a study of GLPG1205 demonstrated positive pharmacokinetics, safety and tolerability; however, the efficacy endpoints were not met in patients with UC, according to a press release.
The data showed GLPG1205 was not significantly superior to placebo as measured by partial Mayo scores, although the agent was shown to be safe and well-tolerated overall.
“Exposure data were in line with the healthy volunteer data from the previous phase 1 clinical study,” according to the press release.
Detailed data from the study will be published later this year, and Galapagos will determine whether GLPG1205 will be developed for other indications.